Key Takeaways
- Sector: Healthcare Healthtech & Medtech.
- Geography: United States.
Analysis
US Fertility has reshaped its ownership to accelerate national expansion after a fresh equity arrangement that sees L Catterton join as a co-lead investor and Amulet Capital Partners increase its capital commitment. The deal preserves the practice’s physician-led structure while providing new resources to scale clinics, labs and research initiatives.
The partnership gives the platform additional firepower to broaden access to assisted reproductive technology (ART). Richard Jennings, Chief Executive Officer of US Fertility, said the new investors will help the group reach more patients and enhance clinical programs; the business already treats more than 60,000 new patients a year and reports having supported roughly 400,000 individuals and couples through fertility care.
Amulet Capital Partners — which originally backed the roll‑up and remains a significant shareholder — has increased its stake, signalling continued confidence in the platform model. Jay Rose, Managing Partner at Amulet, highlighted the firm’s experience building physician practice management businesses and said the additional capital reflects conviction in US Fertility’s trajectory.
Joining as co-lead, L Catterton brings consumer-health expertise and operational resources. Rajan Shah, Partner at L Catterton, said the firm will apply its playbook for multi-site service platforms to improve patient experience, accelerate technology adoption and support clinical outcomes across the group’s network of IVF laboratories and clinics.
The organisation operates a large physician network — roughly 200 physicians across about 121 clinic and IVF laboratory locations — and combines clinical services including IVF, IUI, genetic diagnostics, cryogenic storage and ancillary life‑science offerings. Management says the research division and a science-first culture have been important to delivering measurable clinical improvements.
The fertility and ART sector is expanding as demographic shifts, delayed family planning and improved diagnostics increase demand; the global fertility services market is commonly estimated in the tens of billions of dollars and is growing at a high-single-digit compound annual rate. Private equity has been active in consolidating fragmented care providers, where scale can drive better outcomes, standardized protocols and technology-enabled patient journeys.
For US Fertility, the capital injection is intended to fund clinic footprint growth, R&D in embryology and genetics, investment in data and digital tools, and recruitment of specialist teams. The revised ownership keeps physicians materially invested in governance while layering in the strategic, consumer-facing and operational capabilities of two experienced private equity partners. The move positions the business to pursue further consolidation and to push on quality metrics at scale — a priority for payors, referring clinicians and patients alike.